MedTrace Logo

Uromune in Treating Recurrent Urinary Tract Infections in Women

NCT04096820 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2024-05-30

Study results available
· View outcomes & findings →

Summary

To determine the effectiveness and safety of the vaccine Uromune in Canadian women with recurrent urinary tract infection.

Conditions

  • Recurrent Uti

Interventions

BIOLOGICAL

Uromune

2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • J. Curtis Nickel, MD, FRCS · Professor of Urology

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-06
Primary Completion
2022-10-31
Completion
2023-01-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04096820 on ClinicalTrials.gov